← All stocks

Novavax Inc

NVAXBiotechnologyLatest filing used: 2026-11-05Filings on SEC EDGAR ↗

Fast grower

Fair value per share

No filings-based value

Too few comparable years of filings.

Last close

$8.52

Nov 13, 2026

How we decide

Ten years of results

Revenue

$1.1B in FY2025, up 65% on the year before

FY2016: $15MFY2017: $31MFY2018: $34MFY2019: $19MFY2020: $476MFY2021: $1.1BFY2022: $2.0BFY2023: $984MFY2024: $682MFY2025: $1.1B$1B$2BFY16FY19FY22FY25$1.1B
Show as table
YearRevenue
FY2016$15M
FY2017$31M
FY2018$34M
FY2019$19M
FY2020$476M
FY2021$1.1B
FY2022$2.0B
FY2023$984M
FY2024$682M
FY2025$1.1B

Shares outstanding

Share count rose 618% over 9 years

FY2019: 24MFY2020: 58MFY2021: 74MFY2022: 78MFY2023: 101MFY2024: 152MFY2025: 173M0100M200MFY16FY19FY22FY25173.1M
Show as table
YearShares outstanding
FY2016–
FY2017–
FY2018–
FY201924M
FY202058M
FY202174M
FY202278M
FY2023101M
FY2024152M
FY2025173M

No cash earnings in the filings. No dividends paid in these years.

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-11-05. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13. Last close: IEX Historical Data, 2026-11-13.